← Back to Search

Liquid Biopsy NGS Prompt for Lung Cancer (iNUDGE Trial)

N/A

Recruiting

Led By Charu Aggarwal, MD, MPH

Research Sponsored by Charu Aggarwal

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants with a histological, or cytological diagnosis of metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) who have not yet received systemic treatment for metastatic disease.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured up to 1 year from the time of randomization to death from any cause

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a way to use health records to prompt doctors to order molecular tests for lung cancer so they can provide better treatment. It also looks at how successful the prompt is.

Who is the study for?

This trial is for adults with a specific lung cancer type called metastatic non-squamous NSCLC, who haven't started treatment. They must be diagnosed at certain Penn Medicine locations. Pregnant women, children, and prisoners are excluded.

What is being tested?

The study tests an 'EHR-nudge' prompting doctors to order molecular testing when diagnosing advanced lung cancer. The aim is to use test results for informed treatment decisions and understand the nudge's effectiveness.

What are the potential side effects?

Since this trial focuses on improving diagnostic processes rather than testing a drug or therapy, it does not directly involve side effects related to medical interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a type of lung cancer called non-squamous NSCLC and haven't been treated for it since it spread.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured up to 1 year from the time of randomization to death from any cause

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured up to 1 year from the time of randomization to death from any cause

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured up to 1 year from the time of randomization to death from any cause for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Availability of comprehensive molecular test results prior to first line therapy for patients with newly diagnosed mNSq NSCLC

Secondary study objectives

Completion of comprehensive molecular testing & modality used

Overall survival

Reasons for failure to complete comprehensive molecular testing

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Penn Presbyterian Medical CenterExperimental Treatment1 Intervention

All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.

Group II: Penn Medicine New JerseyExperimental Treatment1 Intervention

All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.

Group III: Penn Medicine Lancaster General HealthExperimental Treatment1 Intervention

All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.

0 / 1Eligibility criteria met